Elutia entered into an Asset Purchase Agreement to sell substantially all assets of its SimpliDerm human acellular dermis business to Cellution Biologics for up to $11 million. The deal includes $8 million in cash at closing, up to $2 million tied to technology transfer and manufacturing transition milestones over 18 months, and up to $1 million in quarterly earn-outs. Elutia agreed to five-year non-compete and non-solicit covenants and will provide transition services after closing. The transaction is subject to customary conditions, with closing expected in the second half of 2026.
Agreement details:
- Agreement type: Asset Purchase Agreement to sell SimpliDerm Business
- Counterparty: Cellution Biologics
- Signed / Effective: Jul 16 2026 / Jul 16 2026
- Duration / Termination: N/A
- Reason: Divest SimpliDerm to streamline portfolio and focus on core areas
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.